natgillin/translations-raw huggingface dataset:
Humalog should only be used in children in preference to soluble insulin when a fast action of insulin might be beneficial.
Pri otrocih naj bi zdravilo Humalog uporabili raje kot topni insulin le, kadar bi lahko bilo hitro delovanje insulina koristno.
Humalog takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with regular insulin.
Subkutano dano zdravilo Humalog začne delovati hitro in deluje krajši čas (2 do 5 ur) v primerjavi z navadnim insulinom.
Humalog works more quickly than normal human insulin because insulin lispro has been changed slightly in comparison to human insulin.
Zdravilo Humalog deluje hitreje kakor običajni humani insulin, saj je bil insulin lispro nekoliko spremenjen v primerjavi s humanim insulinom.
Humalog: insulin lispro solution, available in a standard or a higher strength (100 or 200 units/ml);
Humalog: raztopina insulina lispro, na voljo v standardni ali višji jakosti (100 ali 200 enot/ml);
Human albumin
humani albumin
Human albumin solution (containing sodium, sodium caprylate and N-acetyl DL tryptophanate).
Raztopina človeškega albumina (vsebuje natrij, natrijev kaprilat in N-acetil DL triptofanat).
Human albumin, sodium chloride and sodium citrate.2H2O
Humani albumin, natrijev klorid in natrijev citrat.
Human alpha1-proteinase inhibitor has a molecular weight of 51 kDa and belongs to the family of serine protease inhibitors.
Humani zaviralec alfa1- proteinaze ima molekulno maso 51 kDa in sodi v družino zaviralcev serinske proteaze.
Human and animal data demonstrated that the kidney is the major organ responsible for elimination of anakinra.
Podatki pri ljudeh in živalih dokazujejo, da so ledvice glavni organ, odgovoren za izločanje anakinre.
Human anti-mouse antibody positive
pozitiven rezultat preiskave za človeška protitelesa proti mišjim protitelesom
Human anti-murine antibodies
Humana protitelesa proti antigenom glodavcev
Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system.
Humana protitelesa so podvržena endocitotski presnovi v celicah retikuloendotelijskega sistema.
human coagulation factor X
humani koagulacijski faktor X
Human data on the use during pregnancy or lactation and animal reproduction studies are not available.
Podatki o uporabi med nosečnostjo ali dojenjem pri človeku in podatki iz študije vplivov na sposobnost razmnoževanja pri živalih niso na voljo.
Human experience of acute overdose with REYATAZ is limited.
Ni zadostnih izkušenj s prevelikim odmerjanjem zdravila REYATAZ pri človeku.
Human experience with tipranavir overdose is very limited.
Pri ljudeh je na voljo zelo malo izkušenj s prevelikim odmerkom.
Human female fertility may be compromised by treatment with Erivedge (see section 5.3).
Zdravljenje z zdravilom Erivedge lahko zmanjša plodnost priženskah (glejte poglavje 5.3).
Human Fibrinogen
humani fibrinogen
human fibrinogen 79 mg/g human thrombin 726 IU/g
humani fibrinogen 79 mg/g humani trombin 726 i.e./g
Human Fibrinogen and Human Thrombin: Omrix Biopharmaceuticals Ltd.
humani fibrinogen in humani trombin: Omrix Biopharmaceuticals Ltd.
Human fibrinogen vial: Arginine hydrochloride Glycine
Viala s humanim fibrinogenom:
Human Hepatitis B Immunoglobulin
Človeški imunoglobulin proti hepatitisu B
Human hepatitis B immunoglobulin for intramuscular use is bioavailable in the recipient’s circulation after a delay of 2 – 3 days.
Človeški imunoglobulin proti hepatitisu B za intramuskularno uporabo je biološko uporaben v krvnem obtoku prejemnika po 2–3 dneh.
Human hepatitis B immunoglobulin injections can induce a drop in blood pressure with an allergic reaction, even in patients who have tolerated previous treatments with immunoglobulin.
Človeški imunoglobulin proti hepatitisu B lahko sproži padec krvnega tlaka z alergijsko reakcijo, celo pri bolnikih, ki so predhodno prenašali zdravljenje z imunoglobulinom.
Human hepatitis B immunoglobulin should be administrated three to four weeks after vaccination with such a live attenuated vaccine; in case administration of human hepatitis B immunoglobulin is essential within three to four weeks after vaccination, then revaccination should be performed three months after the administration of human hepatitis B immunoglobulin.
Humani imunoglobulin proti hepatitisu tipa B je treba aplicirati od tri do štiri tedne po cepljenju s takšnim živim atenuiranim cepivom; če je dajanje humanega imunoglobulina proti hepatitisu tipa B nujno v obdobju od treh do štirih tednov po cepljenju, je treba tri mesece po dajanju humanega imunoglobulina proti hepatitisu tipa B cepljenje ponoviti.
Human IgG are known to cross the human placental barrier, and thus eculizumab may potentially cause terminal complement inhibition in the foetal circulation.
Za humane IgG je znano, da prehajajo preko humane placentalne bariere, iz česar sledi, da utegne ekulizumab povzročiti zaviranje terminalnega komplementa v obtoku ploda.
Human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology.
Humano monoklonsko protitelo IgG1κ, ki ga izdelujejo v celični liniji mišjega hibridoma s pomočjo tehnologije rekombinantne DNA.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Humani insulin Insulin Human Winthrop je pridobljen s tehnologijo rekombinantne DNA iz bakterij
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Humani insulin Insulin Human Winthropje pridobljen s tehnologijo rekombinantne DNA iz bakterij
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Humani insulin vInsulin Human Winthrop je pridobljen s tehnologijo rekombinantne DNA iz bakterij
Human liver microsome studies identified CYP1A2 and CYP2C8 as the enzymes responsible for eltrombopag oxidation.
Študije s humanimi jetrnimi mikrosomi so pokazale, da sta za oksidacijo eltrombopaga odgovorna encima CYP 1A2 in CYP2C8.
Human normal immunoglobulin (IG 10%) vial
Viala humanega polispecifičnega imunoglobulina (IG 10 %)
Human normal immunoglobulin 10%
Humani polispecifični imunoglobulin 10
Human normal immunoglobulin 100 mg (purity of at least 98% IgG)
Humani polispecifični imunoglobulin 100 mg (čistost vsaj 98 % IgG)
Human normal immunoglobulin is immediately and completely bioavailable in the recipient’s circulation after intravenous administration.
Humani polispecifični imunoglobulin je po intravenski uporabi takoj in v celoti biološko uporaben v krvnem obtoku prejemnika.
Human normal immunoglobulin is immediately and completely bioavailable in the recipient’s circulation after intravenous administration.
Humani polispecifični imunoglobulin je pri intravenski uporabi takoj in popolnoma biološko uporaben v krvnem obtoku prejemnika.
Human normal immunoglobulin should be infused intravenously at an initial infusion rate of 0.3 ml/kg bw/hr for approximately 30 min.
Humani polispecifični imunoglobulin je treba infundirati intravensko, z začetno hitrostjo infundiranja 0,3 ml/kg tm/uro približno 30 minut.
Human overdose experience
Izkušnje s prevelikim odmerjanjem pri človeku
Human paediatric patients are at increased risk for bone and teeth effects as compared to adults, as these changes, including inhibition of growth (shortened limbs), fragile bones and remodelling of teeth, were present in juvenile rats at ≥ 10 mg/kg/day (equal to approximately 0.1-0.2 times the clinical exposure based on AUC in adult humans) (see section 4.4).
Pri človeku obstaja pri pediatričnih bolnikih večje tveganje za učinke na kosti in zobe kot pri odraslih: te spremembe - vključno z zavrtjem rasti (krajši udi), krhkimi kostmi in remodeliranjem zob - so bile pri mladih podganah prisotne pri ≥ 10 mg/kg/dan (to je približno 0,1- do 0,2-kratnik klinične izpostavljenosti na podlagi AUC pri odraslih ljudeh) (glejte poglavje 4.4).
Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
9-valentno cepivo proti humanim papilomavirusom (rekombinantno, adsorbirano)
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)
Adsorbirano rekombinantno cepivo z adjuvansom proti genotipoma 16 in 18 humanih virusov papiloma
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed).
adsorbirano rekombinantno cepivo proti humanim papilomavirusom [tipom 6, 11, 16 in 18]
Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms
L1 protein2,3,4 genotipa 16 humanega virusa papiloma1 20 mikrogramov
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms
L1 protein2,3,4 genotipa 18 humanega virusa papiloma1 20 mikrogramov
Human Papillomavirus1 Type 6 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 20 micrograms
L1 protein2,3 humanega papilomavirusa1 tipa 6 20 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 11 40 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 16 40 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 18 20 mikrogramov
Human Papillomavirus1 Type 6 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 20 micrograms.
L1 protein2,3 humanega papilomavirusa1 tipa 6 20 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 11 40 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 16 40 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 18 20 mikrogramov
Human Papillomavirus1 Type 6 L1 protein2,3 30 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 60 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 31 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 33 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 45 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 52 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 58 L1 protein2,3 20 micrograms
L1 protein2,3 humanega papilomavirusa1 tipa 6 30 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 11 40 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 16 60 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 18 40 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 31 20 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 33 20 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 45 20 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 52 20 mikrogramov L1 protein2,3 humanega papilomavirusa1 tipa 58 20 mikrogramov
Human Papillomavirusa Type 6 L1 proteinb,c 20 micrograms Human Papillomavirusa Type 11 L1 proteinb,c 40 micrograms Human Papillomavirusa Type 16 L1 proteinb,c 40 micrograms Human Papillomavirusa Type 18 L1 proteinb,c 20 micrograms aHuman Papillomavirus = HPV
L1 proteinb,c humanega papilomavirusaa tipa 6 20 mikrogramov L1 proteinb,c humanega papilomavirusaa tipa 11 40 mikrogramov L1 proteinb,c humanega papilomavirusaa tipa 16 40 mikrogramov L1 proteinb,c humanega papilomavirusaa tipa 18 20 mikrogramov ahumani papilomavirus = HPV
Human plasma
humana plazma
Human plasma protein binding is approximately 75% following a single dose of Victrelis 800 mg.
Vezava na humane beljakovine v plazmi je po enkratnem odmerku 800 mg zdravila Victrelis približno 75 %.
Human Protein C
Humani protein C
Human rotavirus RIX4414 strain (live, attenuated) not less than 106.0 CCID50
Humani rotavirus, sev RIX4414 (živ, atenuiran) ne manj kot 106,0 CCID50
Human rotavirus RIX4414 strain (live, attenuated)* not less than 106.0 CCID50
Humani rotavirus, sev RIX4414 (živ, atenuiran)* ne manj kot 106,0 CCID50
Human serum albumin Dibasic sodium phosphate Monobasic sodium phosphate Sodium chloride
humani serumski albumin natrijev hidrogenfosfat natrijev dihidrogenfosfat natrijev klorid
Human serum albumin Water for injections
humani serumski albumin voda za injekcije
Human serum albumin, sodium chloride, di- and monobasic sodium phosphate.
humani serumski albumin, natrijev klorid, natrijev hidrogenfosfat in natrijev dihidrogenfosfat
Human studies evaluating the interaction of safinamide with CYP1A2 and CYP3A4 substrates (caffeine and midazolam), did not demonstrate any clinically significant effects on the pharmacokinetic profile of safinamide.
Študije pri ljudeh, ki so ocenjevale medsebojno delovanje safinamida in substratov CYP1A2 in CYP3A4 (kofein in midazolam), niso pokazale klinično pomembnih učinkov na farmakokinetični profil safinamida.
Human Thrombin 40 IU Contains one sealant matrix (5.1 cm x 10.2 cm)
Vsebuje en matriks z lepilom za tkiva (5,1 cm × 10,2 cm)
Human thrombin:
humani trombin
HUMENZA consists of 2 separate vials:
Cepivo HUMENZA je sestavljeno iz dveh vial:
HUMENZA consists of 2 separate vials:
Zdravilo HUMENZA je sestavljeno iz dveh ločenih vial:
Humenza has been given ‘Conditional Approval’.
Za zdravilo Humenza je bila sprejeta „pogojna odobritev“.
Humenza is a vaccine to protect against ‘pandemic’ flu.
Zdravilo Humenza je cepivo za zaščito pred pandemično gripo.
HUMENZA is not recommended in children below 6 months of age.
Uporaba cepiva HUMENZA pri otrocih v starosti pod 6 meseci ni priporočljiva.
HUMENZA should be stored in a refrigerator (2°C-8°C) and should be used within 24 hours
Cepivo HUMENZA shranjujte v hladilniku (2 °C–8 °C) in uporabite v 24 urah.
HUMENZA should under no circumstances be administered intravascularly.
Zdravilo HUMENZA se pod nobenim pogojem ne sme dajati intravaskularno.
HUMENZA suspension and emulsion for emulsion for injection Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
HUMENZA suspenzija in emulzija za emulzijo za injiciranje cepivo proti pandemski gripi (H1N1) (delci viriona, inaktivirani, z adjuvansom)
Humira
34 (27.9%)
Humira
40 (26.0%)
Humira ( N = 30)
Zdravilo Humira (N = 30)
Humira (N = 30)
Zdravilo Humira (N = 30)
Humira / MTX (N = 38)
Zdravilo Humira (n = 38)
Humira /MTX (N = 38)
Zdravilo Humira / MTX (N = 38)
Humira /MTX (N = 38)
Zdravilo Humira/Metotreksat e (N = 38)
Humira 160/80 mg N=159
Humira 80/40 mg
Humira 40 mg eow N=814 n (%)
Zdravilo Humira n = 151
Humira 40 mg every other week was assessed in 185 patients in one randomised, 12 week double - blind, placebo - controlled study in patients with active non-radiographic axial spondyloarthitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients treated with Humira and 6.5 for those on placebo) who have had an inadequate response to or intolerance to  1 NSAIDs, or a contraindication for NSAIDs.
Uporabo zdravila Humira 40 mg vsak drugi teden so proučili v randomizirani, 12 tednov trajajoči, dvojno slepi, s placebom kontrolirani študiji pri 185 bolnikih z aktivnim ne-radiografskim aksialnim spondiloartritisom (srednja vrednost aktivnosti bolezni [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] je bila 6,4 pri bolnikih zdravljenih z zdravilom Humira in 6,5 pri bolnikih na placebu), ki so nezadostno reagirali na ali niso prenašali vsaj enega NSAID ali s kontraindikacijo za NSAID.
Humira 40 mg every other week was assessed in 393 patients in two randomised, 24 week double − blind, placebo − controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy.
Humiro 40 mg vsak drugi teden so ocenili v dveh randomiziranih 24-tedenskih dvojno slepih, s placebom kontroliranih študijah pri 393 bolnikih z aktivnim ankilozirajočim spondilitisom (povprečna izhodiščna ocena aktivnosti bolezni [indeks BASDAI (Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa – Bath Ankylosing Spondylitis Disease Activity Index)] je bil v vseh skupinah 6,3), ki se niso odzvali ustrezno na konvencionalno terapijo.
Humira 40 mg every other week was assessed in 393 patients in two randomised, 24 week double − blind, placebo − controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy.
Zdravilo Humira 40 mg so vsak drugi teden ocenili v dveh randomiziranih 24-tedenskih dvojno slepih, s placebom kontroliranih študijah pri 393 bolnikih z aktivnim ankilozirajočim spondilitisom (povprečna izhodiščna ocena aktivnosti bolezni [indeks BASDAI (Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa – Bath Ankylosing Spondylitis Disease Activity Index)] je bil v vseh skupinah 6,3), ki se niso odzvali ustrezno na konvencionalno terapijo.
Humira 40 mg every other week was assessed in 393 patients in two randomised, 24 week double − blind, placebo − controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy.
Zdravilo Humira 40 mg vsak drugi teden so ocenili v dveh randomiziranih 24-tedenskih dvojno slepih, s placebom kontroliranih študijah pri 393 bolnikih z aktivnim ankilozirajočim spondilitisom (povprečna izhodiščna ocena aktivnosti bolezni [indeks BASDAI (Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa – Bath Ankylosing Spondylitis Disease Activity Index)] je bil v vseh skupinah 6,3), ki se niso odzvali ustrezno na konvencionalno terapijo.
Humira 40 mg injection adalimumab Subcutaneous use
Humira 40 mg injekcija adalimumab subkutana uporaba
Humira 40 mg solution for injection in pre-filled pen
Humira 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
Humira 40 mg solution for injection in pre-filled pen adalimumab
Humira 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab
Humira 40 mg solution for injection in pre-filled pen is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.4 ml solution.
Zdravilo Humira 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku je na voljo kot sterilna raztopina 40 mg adalimumaba, raztopljenega v 0,4 ml raztopine.
Humira 40 mg solution for injection in pre-filled pen is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution.
Zdravilo Humira 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku je na voljo kot sterilna raztopina 40 mg adalimumaba, raztopljenega v 0,8 ml raztopine.
Humira 40 mg solution for injection in pre-filled syringe
Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Humira 40 mg solution for injection in pre-filled syringe adalimumab
Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi adalimumab
Humira 40 mg solution for injection in pre-filled syringe is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.4 ml solution.
Zdravilo Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi je na voljo kot sterilna raztopina 40 mg adalimumaba, raztopljenega v 0,4 ml raztopine.
Humira 40 mg solution for injection in pre-filled syringe with needleguard
Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi s ščitnikom za iglo
Humira 40 mg solution for injection in pre-filled syringe with needleguard adalimumab
Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi s ščitnikom za iglo adalimumab
Humira 40 mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled syringe.
Zdravilo Humira 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku za enkratno uporabo, ki ga uporabi bolnik, vsebuje napolnjeno injekcijsko brizgo.
Humira 40 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper (bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).
Zdravilo Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi (steklo tipa I) z batno zaporko (bromobutilni kavčuk) in z iglo z varovalnim pokrovčkom (termoplastični elastomer).
Humira 40 mg solution for injection in single-use pre-filled syringe (type I glass) with needleguard for hospital and caregiver use.
Zdravilo Humira 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi (steklo tipa I) za enkratno uporabo, opremljeni s ščitnikom za iglo, za zdravniško in bolnišnično uporabo.
Humira 40 mg weekly
Humira 40 mg vsak teden
Humira 40 mg Weekly
Zdravilo Humira 40 mg
Humira 40 mg/0.8 ml injection Subcutaneous use adalimumab
Humira 40 mg/0,8ml injekcija s.c. adalimumab
Humira 40 mg/0.8 ml solution for injection for paediatric use adalimumab
Humira 40 mg/0,8ml raztopina za injiciranje za pediatrično uporabo adalimumab
Humira 40 mg/0.8 ml solution for injection for paediatric use.
Humira 40 mg/0,8 ml raztopina za injiciranje za pediatrično uporabo
Humira 40mg every other week was assessed in 185 patients in one randomised, 12 week double - blind, placebo - controlled study in patients with active non-radiographic axial spondyloarthitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients treated with Humira and 6.5 for those on placebo) who have had an inadequate response to or intolerance to  1 NSAIDs, or a contraindication for NSAIDs.
Uporabo zdravila Humira 40 mg vsak drugi teden so proučili v randomizirani, 12 tednov trajajoči, dvojno slepi, s placebom kontrolirani študiji pri 185 bolnikih z aktivnim ne-radiografskim aksialnim spondiloartritisom (srednja vrednost aktivnosti bolezni [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] je bila 6,4 pri bolnikih zdravljenih z zdravilom Humira in 6,5 pri bolnikih na placebu), ki so nezadostno reagirali na ali niso prenašali vsaj enega NSAID ali s kontraindikacijo za NSAID.
Humira 80/40 mg N = 75
Zdravilo Humira 80/40 mg n = 75
Humira also produced a greater improvement in symptoms than placebo (a dummy treatment) in studies of psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis without evidence in the X- ray of ankylosing spondylitis but with objective signs of inflammation, and induction and maintenance phases of treatment for Crohn’s disease, psoriasis and ulcerative colitis.
Zdravilo Humira je bolj izboljšalo simptome kot placebo (zdravilo brez zdravilne učinkovine) v študijah psoriatičnega artritisa, ankilozirajočega spondilitisa, aksialnega spondiloartritisa, pri katerem ankilozirajoči spondilitis ni dokazan z rentgenskim slikanjem, a je opaziti znake vnetja, ter pri uvodni in vzdrževalni fazi zdravljenja Crohnove bolezni, psoriaze in ulceroznega kolitisa.
Humira belongs to a group of medicines that block the activity of tumour necrosis factor (TNF) in the body (TNF blockers).
Zdravilo Humira spada v skupino zdravil, ki zavirajo tumorje nekrotizirajoči faktor (TNF) v telesu (TNF zaviralci).
Humira can be taken together with:
Zdravilo Humira se lahko uporablja skupaj z:
Humira can cause reactivation of HBV in people who carry this virus.
Zdravilo Humira lahko pri nosilcih HBV povzroči reaktivacijo tega virusa.
Humira can slow down the damage to the joints caused by the disease and can help them move more freely.
Zdravilo Humira lahko upočasni napredovanje prizadetosti sklepov, ki jo povzroči bolezen, in jim lahko pomaga, da se bolj svobodno gibljejo.
Humira can slow down the damage to the joints caused by the inflammatory disease and can help them move more freely.
Zdravilo Humira lahko upočasni okvaro sklepov, ki jo povzroča ta vnetna bolezen in jim lahko pomaga, da se bolj svobodno gibljejo.
Humira contains the active substance adalimumab, a selective immuno suppressive agent.
Zdravilo Humira vsebuje zdravilno učinkovino adalimumab, selektivni zaviralec imunskega sistema.
Humira contains the active substance adalimumab, a selective immunosuppressive agent.
Zdravilo Humira vsebuje zdravilno učinkovino adalimumab, selektivni zaviralec imunskega sistema.
Humira contains the active substance adalimumab, which is a human monoclonal antibody.
Zdravilo Humira vsebuje zdravilno učinkovino adalimumab, ki je humano monoklonsko protitelo.
Humira does not contain preservatives.
Zdravilo Humira ne vsebuje konzervansov.